Olaparib in PALB2 Advanced Pancreatic Cancer

Summary

This is a Phase II, non-randomized, multicenter, unblinded open-label study of Olaparib in monotherapy in participants with advanced (locally advanced/metastatic) PALB2-related pancreatic cancer that have progressed after at least one treatment for advanced disease.

Timeline

Start

2023-08-01

Primary completion

2025-08-01

Completion

2026-08-01

Drugs

Indications